Last reviewed · How we verify

NCT05678712

Improved Glycemic Control in Diabetic Patients in Hemodialysis Using Continuous Glucose Monitoring (CGM)

Completed NA Last updated 31 January 2024
What this trial tests

NA trial testing Access to CGM data (Dexcom G6) in Hemodialysis in 23 participants. Completed in 18 December 2023.

Timeline
9 March 2022
Primary endpoint
18 December 2023
18 December 2023

Quick facts

Lead sponsorAalborg University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment23
Start date9 March 2022
Primary completion18 December 2023
Estimated completion18 December 2023
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Aalborg University Hospital

Who can join

18 and older, any sex, with Hemodialysis or Type1diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The 16-week trial is an open-label cross-over trial which includes heamodialysis patients with T2D and T1D on insulin therapy. During one period, patients carry a non-blinded CGM. In the other period they follow standard procedures (the last two weeks with a blinded CGM). The patients and the dialysis staff can use the CGM measures to regulate insulin and food intake during the non-blinded weeks. The research group will collect the CGM-data during the trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hemodialysis

Currently open trials in the same condition.

Other Aalborg University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing